Al Zahra Hospital Introduces Blenrep in Gulf – First Commercial Use for Multiple Myeloma
– Dubai, United Arab Emirates
Regional Milestone in Cancer Treatment
Al Zahra Hospital Dubai administered the first commercial dose of Blenrep (belantamab mafodotin) in the Gulf on 27 January 2026. The infusion represents the culmination of years of regulatory coordination, clinical preparation, and strategic investment in advanced oncology care.
The novel antibody‑drug conjugate (ADC) targets the B‑cell maturation antigen (BCMA) on malignant plasma cells, offering a new therapeutic option for patients with relapsed or refractory multiple myeloma (RRMM) who have exhausted standard salvage regimens.
Understanding Blenrep: From Bench to Bedside
Blenrep received accelerated approval from the U.S. Food and Drug Administration in 2020 based on the DREAMM‑2 trial, which showed an overall response rate of 31 % in heavily pre‑treated RRMM patients.[1] The drug combines a humanized monoclonal antibody against BCMA with the cytotoxic payload monomethyl auristatin‑F, delivering cell‑killing activity directly to cancer cells while sparing most healthy tissue.
- Median progression‑free survival: 7.2 months in patients with ≥ three prior lines of therapy.
- Durable responses observed, including complete remissions lasting > 12 months in a subset.
- Manageable safety profile; corneal toxicity is the most notable adverse event and is mitigated through regular ophthalmologic monitoring.
These data have led to Blenrep’s inclusion in multiple national multiple‑myeloma guidelines worldwide.
Path to Commercial Availability in the Gulf
The drug’s regional launch required coordinated action across four key domains:
- Regulatory Clearance – The UAE Ministry of Health and Prevention granted a conditional marketing authorization in September 2025 after reviewing local pharmacovigilance data and GMP compliance.[2]
- Supply Chain Logistics – A cold‑chain network maintaining –20 °C was established with a regional distributor to preserve the ADC’s stability.
- Clinical Infrastructure – Al Zahra upgraded its oncology infusion suites with laminar‑flow hoods, ocular monitoring stations, and trained nursing staff on the specific Blenrep protocol.
- Patient Selection Framework – A multidisciplinary tumor board set criteria for RRMM patients who have failed proteasome inhibitors, IMiDs, and anti‑CD38 antibodies.
Impact on Patients and the Healthcare Ecosystem
The first recipient, a 62‑year‑old Emirati male with a five‑year history of multiple myeloma, showed a rapid decline in serum M‑protein levels after two treatment cycles. While long‑term outcomes remain under observation, the early response suggests potential for extended survival and improved quality of life.
Broader Systemic Benefits
- Reduced Medical Tourism – Patients no longer need to travel abroad for this therapy, conserving financial and emotional resources.
- Enhanced Clinical Research Capacity – Al Zahra can now participate in post‑marketing surveillance and real‑world evidence studies specific to Middle‑Eastern populations.
- Catalyst for Further Innovation – Successful rollout may encourage pharmaceutical firms to prioritize the Gulf for upcoming ADCs, CAR‑T cell therapies, and other precision‑medicine modalities.
Voices from the Frontline
Dr. Mona Al Saeed, Head of Hematology: “Blenrep represents a paradigm shift for myeloma patients who have exhausted conventional options. Our team has worked tirelessly to ensure safe administration with rigorous ocular monitoring and patient education. This milestone reflects the UAE’s commitment to delivering world‑class oncology care within our own borders.”
Khaled Al Mansoor, Pharmacist: “The logistical challenges of an ADC—temperature control, precise reconstitution, and timing—are non‑trivial. Our successful rollout demonstrates that with the right infrastructure and interdisciplinary collaboration, we can bring the most advanced therapies to our community.”
Looking Ahead: Sustainability and Access
Despite the breakthrough, the high cost of Blenrep poses a barrier to widespread public‑sector adoption. Al Zahra is negotiating reimbursement pathways with MOHAP and private insurers to balance fiscal responsibility with patient access.
A comprehensive patient‑support program is planned, encompassing:
- Regular ophthalmologic assessments to manage corneal toxicity.
- Education on side‑effect recognition and mitigation.
- Psychosocial counseling for patients and families.
These measures aim to sustain treatment adherence and maximize therapeutic benefit.
Conclusion
Al Zahra Hospital’s administration of Blenrep marks the first commercial deployment of this BCMA‑targeted ADC in the Gulf, establishing a benchmark for next‑generation oncology therapeutics in the Middle East. By overcoming regulatory, logistical, and clinical hurdles, the hospital has opened a new therapeutic avenue for refractory multiple myeloma patients while strengthening the region’s capacity for advanced cancer care.
The initiative underscores a strategic vision to transform the Gulf into a destination where cutting‑edge medical innovations are seamlessly integrated into local practice, ultimately improving outcomes for patients across the Arabian Peninsula.
